RxDoctor Payments DataLook up a doctor →

Stacey Coyle

Family · Sewickley, PANPI 1316585474

Payments from drug & device makers

$14,618in general payments, 2019–2025

Across 899 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • GSK$887
  • Pfizer$879
  • Amgen$698
  • plus $7K from 48 others

What the payments were for

  • Food & beverage$14,49399%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,618 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,744
Medicare patients
161
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$44,106
MounjaroTirzepatide16$26,550
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$24,394
OzempicSemaglutide22$23,969
JardianceEmpagliflozin28$22,983
FarxigaDapagliflozin Propanediol19$17,610
MyrbetriqMirabegron12$16,064
XareltoRivaroxaban12$11,632
VoqueznaVonoprazan Fumarate14$8,996
Breo ElliptaFluticasone/Vilanterol13$5,210
Fluticasone Propionate183$2,439
Albuterol Sulfate HfaAlbuterol Sulfate84$1,998
Rosuvastatin Calcium127$1,993
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,956
Clobetasol Propionate20$1,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$879$44,10633 claims
GSKTrelegy Ellipta, Breo Ellipta$887$29,60436 claims
Lilly USA, LLCMounjaro$1,098$26,55016 claims
Novo NordiskOzempic$1,627$23,96922 claims
Boehringer IngelheimJardiance$566$22,98328 claims
AstraZenecaFarxiga$446$17,61019 claims
Astellas Pharma US IncMyrbetriq$261$16,06412 claims
Johnson & JohnsonXarelto$486$11,63212 claims
Phathom Pharmaceuticals, Inc.Voquezna$147$8,99614 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$72089 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Sewickley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →